Stuart Rich has bought TENX on 2 days since Dec 2025

Dr. Stuart Rich is the Chief Medical Officer and a Director of Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing therapies for pulmonary hypertension and other cardiovascular conditions.( As CMO, he plays a central role in the company’s clinical strategy and participates in earnings calls alongside the chief executive officer to discuss pipeline progress and trial data.( In January 2026, Tenax disclosed an amendment to his employment agreement under which Dr. Rich will devote an average of four days per week to his CMO duties, with a prorated salary effective January 1, 2026.(

Dr. Rich is also a notable corporate insider at Tenax Therapeutics. In December 2025, he reported purchasing a total of 5,000 shares of Tenax common stock in two open-market transactions totaling approximately $50,792, at prices ranging from $10.1002 to $10.2168 per share.( Following these trades, he directly owned 5,266 shares and indirectly held additional shares through the Stuart Rich Revocable Trust DTD 11/18/1996, the Stuart Rich 2022 Irrevocable Trust, and the Andrea Rich 2021 Irrevocable Trust, and also held stock options to purchase further shares.( Public filings and available summaries emphasize his executive leadership and insider ownership at Tenax but do not provide detailed information on his earlier career history or formal education.(

Written by Perplexity from public sources.